July 31, 2014 /3BL Media/ - Earlier this month, at the 11th annual Pocono Mountains Community Fundraiser, Sanofi Pasteur executives revealed more than $2 million has been raised through its ongoing signature fundraising programs. These programs benefit critical Pennsylvania community non-profit organizations.
The recent measles outbreaks in communities around the country serve as a stark reminder that when large groups of people are unvaccinated, it leaves them unprotected and vulnerable to disease outbreaks.
East Stroudsburg, PA, December 20, 2013 – Sanofi Pasteur, the vaccines division of Sanofi, announced today that its employees and contractors collected and hand-delivered a record number of gifts, non-perishable food items, and supermarket gift cards to Pocono Services for Families and Children (PSFC). These contributions will benefit the non-profit organization’s neediest families.
Vaccine Discovery Partnership (VxDP) announcement at the Foundation’s Grand Challenges Meeting in Rio de Janeiro signals commitment to find solutions to the challenges facing the developing world
October 30, 2013 /3BL Media/ - GSK and the Bill & Melinda Gates Foundation (BMGF) today announced the launch of a new joint initiative that will endeavour to make vaccines more resistant to heat, thus reducing the need for refrigeration. GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability.
Most vaccines must be kept cold and transported under constant refrigeration via a so-called ‘cold chain’ which is a significant challenge in hot, remote and resource-limited regions.
JPMorgan Chase, the Bill & Melinda Gates Foundation and partners announce successful capital raise for first-of-its-kind investment product
NEW YORK, September 23, 2013 /3BL Media/ - A new investment fund structured by JPMorgan Chase & Co. (NYSE: JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.
Last night, GSK was honoured by The Pharmaceutical Research and Manufacturers of America (PhRMA) with the "The Research and Hope Award" which highlights individuals or a team from a biopharmaceutical company for outstanding research in the area ofvaccines.
Collaborative study utilizing Vaccine Safety Datalink published in the American Journal of Preventive Medicine
San Diego, CA, June 11, 2013 /3BL Media/ – In a study using the Vaccine Safety Datalink (VSD), investigators analyzed four years of data and determined that background mortality rates (rates of death irrespective of cause) are crucial in interpreting the numbers of deaths following vaccination. The VSD mortality rate following immunization is lower than the general US population mortality rate, and the causes of death are similar. These background rates can be used in communications to the public about vaccine safety risks, reports the American Journal of Preventive Medicine.
May 10, 2013 /3BL Media/ - GlaxoSmithKline (GSK) today announced a new commitment to the GAVI Alliance to supply its cervical cancer vaccine as part of a new long term programme to help protect girls against cervical cancer in the world’s poorest countries. To start the programme and over the next two years, GSK will supply doses of Cervarix® (Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)) to four new GAVI demonstration projects at a significantly discounted price of $4.60 per dose.
Company also expands injectable polio vaccine production capacity to respond to the World Health Organization's endgame strategy
April 24, 2013 /3BL Media/ - Sanofi Pasteur, the vaccines division of Sanofi, announced today its commitment to provide 1.7 billion doses of oral polio vaccine (OPV) to support the Global Polio eradication Initiative’s (GPEI) strategy to eradicate polio this decade. The doses of OPV will be delivered through 2017 for GPEI polio vaccination program.